个人简历
叶茂：博士生导师，化学生物传感与计量学国家重点实验室/湖南大学生物学院/湖南大学分子科学与生物医学实验室教授。2007年－2010年于美国纽约血液中心Lindsley F. Kimball Research Institute (LFKRI)从事博士后研究工作。2013年入选教育部新世纪优秀人才。担任湖南省生物化学与分子生物学学会理事、中国转化医学联盟云南省转化医学分会常务委员、全国科学技术名词审定委员会肿瘤学名词编写委员会编委。主持国家自然科学基金、湖南省重点研发计划、湖南省自然科学基金、浙江省自然科学基金、长沙市科技计划等多项。获得国家授权发明专利五项。发表SCI论文近五十篇，其中第一或通讯作者在PNAS、Trends Biochem Sci、Angew. Chem. Int. Ed、Theranostics、Chemical Science等国际学术期刊上发表SCI论文文章近三十篇。 2009年获得教育部高等学校科学研究优秀成果二等奖，2010年获得湖南省自然科学一等奖，2017年获得湖南省自然科学二等奖。教育背景 2005年毕业于中南大学湘雅医学院肿瘤研究所，获得医学博士学位。
研究领域
从事肿瘤生物学、抗肿瘤分子靶向治疗、化学生物学等方向的研究工作。研究具体内容以恶性肿瘤细胞增殖、分化、转移、凋亡等生物学行为为切入点，通过分子生物学、基因组学和蛋白质组学的方法和手段，探讨恶性肿瘤发生、发展的分子病理学机制，寻找恶性肿瘤的早期诊断、治疗或预后有指导意义的分子标志物和分子靶标，并借助生物分析和功能纳米材料的方法和手段，开展恶性肿瘤分子成像、分子诊断和分子靶向治疗。
近期论文
[1] Zhou, Weihua; Zhang, Yibin; Zeng, Yayue; Peng, Minyuan; Li, Hui; Sun, Shuming; Ma, Bianying; Wang, Yanpeng; Ye, Mao*; Liu, Jing*. Screening and characterization of a Annenix A2 binding aptamer that inhibits the proliferation of myeloma cells, Biochimie, (2018). [2] Zhang, Hui; Wang, Zhibo; Xie, Lin; Zhang, Yibin; Deng, Tanggang; Li, Jianglin; Liu, Jing; Xiong, Wei; Zhang, Lei; Zhang, Lin; Peng, Bo; He, Leye; Ye, Mao*, Hu, Xiaoxiao*; Tan, Weihong*. Molecular Recognition and In-Vitro-Targeted Inhibition of Renal Cell Carcinoma Using a DNA Aptamer, Molecular Therapy-Nucleic Acids, 12 (2018) 758-768. [3] Roy, Mridul; Liang, Long; Xiao, Xiaojuan; Feng, Peifu; Ye, Mao*; Liu, Jing*. Lycorine: A prospective natural lead for anticancer drug discovery, Biomedicine & Pharmacotherapy, 107 (2018) 615-624. [4] Jin, Cheng#; Zhang, Hui#; Zou, Jianmei; Liu, Yan; Zhang, Lin; Li, Fengjie; Wang, Ruowen; Xuan, Wenjing; Ye, Mao*; Tan, Weihong*. Floxuridine Homomeric Oligonucleotides “Hitchhike” with Albumin In Situ for Cancer Chemotherapy, Angewandte Chemie International Edition, 57 (2018) 8994-8997. [5] Fu, Ting#; Lyu, Yifan#; Liu, Hui; Peng, Ruizi; Zhang, Xiaobing; Ye, Mao*; Tan, Weihong*. DNA-Based Dynamic Reaction Networks, Trends in Biochemical Sciences, (2018). [6] Deng, Tanggang#; Yan, Guobei#; Song, Xin#; Xie, Lin; Zhou, Yu; Li, Jianglin; Hu, Xiaoxiao; Li, Zhen; Hu, Jun; Zhang, Yibin; Zhang, Hui; Sun, Yang; Feng, Peifu; Wei, Dong; Hu, Bin; Liu, Jing*; Tan, Weihong*; Ye, Mao*. Deubiquitylation and stabilization of p21 by USP11 is critical for cell-cycle progression and DNA damage responses, Proceedings of the National Academy of Sciences, 115 (2018) 4678-4683. [7] Chen, Jieying#; Sheng, Xunan#; Ma, Hongchang#; Tang, Zhengshan; Yang, Chao; Cao, Lanqin; Sun, Yang; Deng, Tanggang; Feng, Peifu; Hu, Bin; Wei, Dong; Liu, Jing; Xiong, Wei*; Ye, Mao*. WDR79 mediates the proliferation of non‐small cell lung cancer cells by regulating the stability of UHRF1, Journal of cellular and molecular medicine, 22 (2018) 2856-2864. [8] Yi, Yi; Wang, Huijing; Wang, Xuewei; Liu, Qiaoling*; Ye, Mao*; Tan, Weihong, A Smart, Photocontrollable Drug Release Nanosystem for Multifunctional Synergistic Cancer Therapy, ACS applied materials & interfaces, 9 (2017) 5847-5854. [9] Wang, Zi; Zhang, Jingxin; Zeng, Yayue; Sun, Shuming; Zhang, Ji; Zhang, Bin; Zhu, Min; Ouyang, Ruoyun; Ma, Bianyin; Ye, Mao*; An, Xiuli*; Liu, Jing*. Knockout of 4.1 B triggers malignant transformation in SV40T‐immortalized mouse embryo fibroblast cells, Molecular carcinogenesis, 56 (2017) 538-549. [10] Sun, Yang#; Cao, Lanqin#; Sheng, Xunan; Chen, Jieying; Zhou, Yu; Yang, Chao; Deng, Tanggang; Ma, Hongchang; Feng, Peifu; Liu, Jing; Tan, Weihong*; Ye, Mao*. WDR79 promotes the proliferation of non-small cell lung cancer cells via USP7-mediated regulation of the Mdm2-p53 pathway, Cell death & disease, 8 (2017) e2743. [11] Peng, Yongbo#; Zhao, Zilong#; Liu, Teng#; Xie, Guojian; Jin, Cheng; Deng, Tang gang; Sun, Yang; Li, Xiong; Hu, Xiaoxiao; Zhang, Xiaobing; Ye, Mao; Tan, Weihong*. A Multi‐Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance, ChemMedChem, 12 (2017) 250-256. [12] Peng, Minyuan; Li, Yanming; Zhang, Jian; Wu, Yong; Yang, Xiaoyang; Lei, Ye; Ye, Mao; Liu, Jing; Han, Xu; Kuang, Yijin; Zhao, Xielan; Chen, Fangping*. Vector-independent transmembrane transport of oligodeoxyribonucleotides involves p38 mitogen activated protein kinase phosphorylation, Scientific reports, 7 (2017) 13571. [13] Jin, Cheng#; Fu, Ting#; Wang, Ruowen*; Liu, Hui; Zou, Jianmei; Zhao, Zilong; Ye, Mao; Zhang, Xiaobing; Tan, Weihong*. Fluorinated molecular beacons as functional DNA nanomolecules for cellular imaging, Chemical science, 8 (2017) 7082-7086. [14] Hu, Jingping; Ye, Mao; Zhou, Zhiguang*, Aptamers: novel diagnostic and therapeutic tools for diabetes mellitus and metabolic diseases, Journal of Molecular Medicine, 95 (2017) 249-256. [15] Han, Xu; Zhang, Jieying; Peng, Yuanliang; Peng, Minyuan; Chen, Xiao; Chen, Huiyong; Song, Jianhui; Hu, Xiao; Ye, Mao; Li, Jianglin; Sankaran,Vijay G; Hillyer, Christopher D; Mohandas, Narla; An, Xiuli; Liu, Jing.Unexpected role for p19INK4d in posttranscriptional regulation of GATA1 and modulation of human terminal erythropoiesis, Blood, 129 (2017) 226-237. [16] Wang, Zi#; Ma, Bianyin#; Li, Hui#; Xiao, Xiaojuan#; Zhou, Weihua; Liu, Feng; Zhang, Bin; Zhu, Min; Yang, Qin; Zeng, Yayue; Sun, Yang; Sun, Shuming; Wang, Yanpeng; Zhang, Yibin; Weng, Haibo; Chen, Lixiang; Ye, Mao*; An, Xiuli*; Liu, Jing*. Protein 4.1 N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC, Oncotarget, 7 (2016) 509. [17] Wang, Ruowen*,#; Lu, Danqing#; Bai, Huarong#; Jin, Cheng; Yan, Guobei; Ye, Mao; Qiu, Liping; Chang, Rongshan; Cui, Cheng; Liang, Hao; Tan, Weihong*. Using modified aptamers for site specific protein–aptamer conjugations, Chemical science, 7 (2016) 2157-2161. [18] Sun, Yang#; Yang, Chao#; Chen, Jieying; Song, Xin; Li, Zhen; Duan, Minlan; Li, Jianglin; Hu, Xiaoxiao; Wu, Kuangpei; Yan, Guobei; Yang, Cai; Liu, Jing; Tan, Weihong*; Ye, Mao*. Overexpression of WDR 79 in non‐small cell lung cancer is linked to tumour progression, Journal of cellular and molecular medicine, 20 (2016) 698-709.
